The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move that strengthens scientific confidence within the biotech sector, Capricor Therapeutics announced that The Lancet has published results from its pivotal Phase 3 HOPE-3 clinical trial. The published data demonstrated that Deramiocel slowed the decline of upper limb function by 54% in patients with Duchenne muscular dystrophy (DMD). According to reports, the publication confirms that the trial met its primary endpoint with statistical significance (p=0.03).
This external peer-reviewed validation follows a period of extreme volatility for the company's stock, which recently experienced a 67% decline despite the positive clinical findings. Per market data, the publication in a top-tier medical journal provides critical third-party verification of the trial design and findings, serving as a landmark milestone for both the medical community and biotech investors navigating high-risk assets.
Looking ahead, investors are focused on the FDA’s decision regarding the Biologics License Application (BLA) for Deramiocel, which has a target action date of August 22, 2026. While current price data for Capricor Therapeutics is unavailable at this time, market participants are monitoring upcoming catalysts, including the Advisory Committee meeting scheduled for late July 2026, which could further influence the regulatory path.